Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.09 USD | -0.27% | +6.61% | -1.78% |
Apr. 29 | North American Morning Briefing : Investors Brace -2- | DJ |
Mar. 25 | Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.78% | 958M | |
-2.54% | 102B | |
+2.33% | 96.09B | |
+2.13% | 22.28B | |
-17.07% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.83% | 16.09B | |
+6.38% | 13.83B | |
+32.58% | 11.97B |
- Stock Market
- Equities
- SAVA Stock
- News Cassava Sciences, Inc.
- B. Riley Securities Lowers Cassava Sciences' Price Target to $44 from $58, Retains Buy Rating